PlainPharmaWatch

CMS Open Payments · Program Year 2024

Geistlich Pharma, North America, Inc.

Geistlich Pharma, North America, Inc. reported $401,659.29 across General Payments, Research, and Ownership to 2,543 physicians and teaching hospitals across 2,560 transactions.

See the rankings → How this is sourced
$401.7K
All-tracks total
2,560
Transactions
2,543
Recipients
−$254.1K
General Payments vs PY2023

Geistlich Pharma, North America, Inc. reported $401,659.29 across all CMS Open Payments tracks (General + Research + Ownership) to 2,543 physicians and teaching hospitals in Program Year 2024 - ranking #821 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $255,020.29, averaging $157.95 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer geistlich-pharma-north-america-inc Geistlich Pharma, North America, Inc.

$401.7K · #821/1,925 · 0.0% industry · PY2024

  • TOT $401.7K
  • RANK #821
  • SHARE 0.0%
  • TXN 2,560
  • RCP 2,543
  • CAT 4
  • GEN $255.0K
  • ΔGEN −$254.1K
  • TOP1 5.1%
  • PY 2024

Volume peers

Nearest volume peer: Onkos Surgical, Inc. ($402.3K)

Mizuho America, Inc.$403.0KOnkos Surgical, Inc.$402.3KGeistlich Pharma, North Amer…$401.7KAgfa HealthCare Corporation$400.9KOsseus Fusion Systems, LLC$399.7K
All-tracks payment totals near Geistlich Pharma, North America, Inc. (CMS Open Payments PY2024)

Geistlich Pharma, North America, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Geistlich Pharma, North America, Inc.'s CMS-reported General Payments decreased by $254.1K (−49.9%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: GEISTLICH PHARMA, NORTH AMERICA, INC.PY2023: GEISTLICH PHARMA, NORTH AMERICA, INC.PY2024: Geistlich Pharma, North America, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$509.2KPY2024$255.0K
PY2023
$509,160.20
PY2024
$255,020.29

What the Data Shows for Geistlich Pharma, North America, Inc.

$401,659.29: that is what Geistlich Pharma, North America, Inc. reported in payments to 2,543 physicians and teaching hospitals during Program Year 2024, spread across 2,560 transactions ($156.90 per transaction, $157.95 per recipient). The company sits at rank #821 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

The 4-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Food and Beverage" at $142.6K, accounting for 55.9% of this company's General Payments and 2,442 transactions.

General Payment Breakdown by Type

"Food and Beverage" leads Geistlich Pharma, North America, Inc.'s 4-category general-payment breakdown at $142.6K, 55.9% of the reported total.

Geistlich Pharma, North America, Inc. reports 4 general-payment categories - the top three are Food and Beverage (55.9%), Travel and Lodging (29.0%), and Honoraria (11.2%). The remaining 1 category make up 3.9% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

How Geistlich Pharma, North America, Inc. divides its payments

How the reported total splits across payment categories

1. Food and Beverage$142.6K2. Travel and Lodging$73.9K3. Honoraria$28.5K4. Consulting Fee$10.0K
Payment Type Amount Transactions
Food and Beverage $142.6K 2,442
Travel and Lodging $73.9K 92
Honoraria $28.5K 8
Consulting Fee $10.0K 1

Recipient Concentration in General Payments

The five largest recipient relationships account for $48,489.59 (19.0%) of $255,020.29 in this company's General Payments records across 1,635 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Geistlich Pharma, North America, Inc.

The five named recipients with the highest reported General Payments from this company

Lawrence Didomenico$13.0KDavid Urbanek$12.5KSamar Shaikh$10.3KMichelle Butterworth$6.6KAndrew Read-Fuller$6.1K
  1. 1

    Lawrence Didomenico

    $13,000.00 across 2 reported transactions

  2. 2

    David Urbanek

    $12,473.00 across 33 reported transactions

  3. 3

    Samar Shaikh

    $10,306.90 across 17 reported transactions

  4. 4

    Michelle Butterworth

    $6,621.69 across 2 reported transactions

  5. 5

    Andrew Read-Fuller

    $6,088.00 across 3 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Geistlich Pharma, North America, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Geistlich Pharma, North America, Inc..

Esperion Therapeutics, Inc.

HHI 121

Immunitybio, Inc.

HHI 122

Microtransponder, Inc.

HHI 120

Metacel Pharmaceuticals LLC

HHI 123

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Geistlich Pharma, North America, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Geistlich Pharma, North America, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.